Like most biotechs without a drug generating revenue, ImmunoGen's (NASDAQ: IMGN) third-quarter earnings were a review of what it's accomplished and a look at what investors can expect in the future.
Fortunately, it's been a productive year for the company in terms of shoring up its balance sheet. Unfortunately, investors still have a ways to go before the revenue will start rolling in.
Metric
Source: Fool.com